• Coverage of the Graft Versus Host Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Graft Versus Host Disease and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Browse Complete Report @ http:// www. orbisresearch. com / reports / index / graft-vs-host-diseasecompetitive-landscape-technology-and-pipeline-analysis-2017
Some Points From List Of Tables:
Table 1: Collaboration and Deal Values for Graft Versus Host Disease, 2017 Table 2: Licensing Agreement of Companies for Graft Versus Host Disease, 2017 Table 3: Financing Values of Graft Versus Host Disease Table 4: Number of Products Under Development for GVHD, 2017 Table 5: Last Stage Products( Phase III and Filed), 2017 Table 6: Mid Stage Products( Phase II), 2017 Table 7: Early Stage Products( Phase I and IND), 2017 Table 8: Pre-Clinical and Discovery Products, 2017 Table 9: Assessment by Monotherapy Products, 2017 Table 10: Assessment by Route Of Administration, 2017 Table 11: Assessment by Stage and Route Of Administration, 2017 Table 12: Assessment by Molecule Type, 2017 Table 13: Assessment by Stage and Molecule Type, 2017 Figure 1: Types of Graft Versus Host Disease, 2017 Figure 2: Symptoms Of Acute Graft Versus Host Disease, 2017 Figure 3: Symptoms Of Chronic Graft Versus Host Disease, 2017 Figure 4: Pathophysiology of Chronic Graft Versus Host Disease, 2017 Figure 5: Leukemia patient received allogeneic HCT from 1995-2015 Figure 6: Non-Leukemia patient received allogeneic HCT from 1995-2015 Figure 7: Collaboration and deal value, 2017 Figure 8: GVHD designation and Number of Products, 2017 Figure 9: GVHD designation by USFDA and EMA, 2017 Figure 10: Number of GVHD Ongoing Clinical Trials & Completion Year, 2017
For any enquires before buying, connect with us @ enquiry @ orbisresearch. com About Us: www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019